Figure 3. Anti-Tat cellular immune responses.

(A) Percentage of subjects showing anti-Tat specific production of IFN-γ, IL-2 or IL-4, respectively, measured at baseline (blue bar) and up to week 48 after the first immunization (red bar) and stratified by Tat dose (Tat 7.5 µg, n = 35; Tat 30 µg, n = 33 subjects, respectively). (B) Percentage of subjects showing anti-Tat CD4⁺ or CD8⁺ lymphoproliferative responses measured at baseline and up to week 48 and stratified by Tat dose (Tat 7.5 µg, n = 31; Tat 30 µg, n = 31). The analysis was performed using the McNemar's test: *p<0.05, **p<0.01.